{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:36:37Z","timestamp":1788572197003,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"21","license":[{"start":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T00:00:00Z","timestamp":1438041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"The University of Texas MD Anderson Cancer Center","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P01 CA049639"],"award-info":[{"award-number":["P01 CA049639"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Chronic use of tyrosine kinase inhibitors (TKIs) may lead to previously unrecognized adverse events. This study evaluated the incidence of acute kidney injury (AKI) and chronic kidney disease (CKD) in chronic\u2010phase (CP) chronic myeloid leukemia (CML) patients treated with imatinib, dasatinib, and nilotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Four hundred sixty\u2010eight newly diagnosed CP CML patients treated with TKIs were analyzed. The molecular and cytogenetic response data, creatinine, and glomerular filtration rate (GFR) were followed from the start of therapy to the last follow\u2010up (median, 52 months). GFR was estimated with the Modification of Diet in Renal Disease equation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Nineteen patients (4%) had TKI\u2010associated AKI. Imatinib was associated with a higher incidence of AKI in comparison with dasatinib and nilotinib (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.014). Fifty\u2010eight patients (14%) developed CKD while they were receiving a TKI; 49 of these patients (84%) did so while they were being treated with imatinib (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001). Besides imatinib, age, a history of hypertension, and diabetes mellitus were also associated with the development of CKD. In patients with no CKD at the baseline, imatinib was shown to reduce GFR over time. Interestingly, imatinib did not cause a significant decline in the GFRs of patients with a history of CKD. Imatinib, dasatinib, and nilotinib increased the mean GFR after 3 months of treatment, and nilotinib led with the most significant increase (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.001). AKI or CKD had no significant impact on overall cytogenetic and molecular response rates or survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      The administration of TKIs may be safe in the setting of CKD in CP CML patients, but close monitoring is still warranted.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2015;121:3894\u20133904.\n                      <\/jats:bold>\n                      \u00a9\n                      <jats:italic>2015 American Cancer Society<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.29587","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T10:11:13Z","timestamp":1438078273000},"page":"3894-3904","source":"Crossref","is-referenced-by-count":74,"title":["Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors"],"prefix":"10.1002","volume":"121","author":[{"given":"Musa","family":"Yilmaz","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology Baylor College of Medicine Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Lahoti","sequence":"additional","affiliation":[{"name":"Section of Nephrology The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela M.","family":"Nogueras\u2010Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055104"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11520"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.08.026"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237404"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.143"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01035.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G131"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.4.685"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/82012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000079140"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf304"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.4.689"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65484-3"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq715"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00433.x"},{"issue":"1","key":"e_1_2_7_22_1","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_7_25_1","unstructured":"National Comprehensive Cancer Network. Chronic myelogenous leukemia. Version 1.2014.http:\/\/www.nccn.org\/patients\/guidelines\/cml\/index.html. Accessed June2015."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.05.005"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.07.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63651-6"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050532"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)01290-5"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.5.1413"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00728.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M411064200"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65263-7"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V125909"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl691"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590041324.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004050392"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001528"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000202487.68969.f7"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000062836.93496.CE"},{"key":"e_1_2_7_42_1","first-page":"271","article-title":"Multiple roles for platelet\u2010derived growth factor in renal disease","volume":"21","author":"Floege J","year":"1995","journal-title":"Miner Electrolyte Metab"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1988.255.5.C674"},{"key":"e_1_2_7_44_1","first-page":"637","article-title":"Visceral glomerular epithelial cells can proliferate in vivo and synthesize platelet\u2010derived growth factor B\u2010chain","volume":"142","author":"Floege J","year":"1993","journal-title":"Am J Pathol"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.7.2873"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010111158"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2014.02.003"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002374"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29587","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:51:07Z","timestamp":1760302267000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,28]]},"references-count":47,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1002\/cncr.29587"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29587","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,28]]}}}